Efficacy, safety and outcome of selective IL-23 inhibitor risankizumab in induction and maintenance of CD and ulcerative colitis: A systematic review.

Skyrizi (risankizumab-rzaa) - AbbVie, Boehringer Ingelheim

http://www.ncbi.nlm.nih.gov/pubmed/42675740

Abdul Haseeb; Abida Perveen; Asad Mehmood; Muhammad Rizwan Ashraf; Muhammad Waqas Afzal; Ushna Ali

Sep 2, 2026